Xiaoping Su
- Cancer Research top 0.2%
- Cancer Genomics and Diagnostics 22
- Cancer-related molecular mechanisms research 22
- Hematology top 0.5%
- Acute Myeloid Leukemia Research 15
- Oncology top 0.5%
- Genetics top 1%
- Molecular Biology top 1%
- Epigenetics and DNA Methylation 21
- Renal and related cancers 17
-
- Renal cell carcinoma treatment 22
-
- Acute Lymphoblastic Leukemia research 13
-
- Immunotherapy and Immune Responses 12
- Co-authors
- James R. DowningCharles G. MullighanChristopher B. MillerJing MaSheila ShurtleffXuetao CaoChing‐Hon PuiElaine Coustan‐Smith
- Cited by
- Cancer ResearchHematologyOncology
- Partner nations
- United StatesChinaFrance
In The Last Decade
Xiaoping Su
163 papers receiving 11.9k citations
Hit Papers
Peers
Comparison fields: 5 of 141
- Cancer Research 3.6k
- Hematology 2.0k
- Oncology 2.8k
- Genetics 933
- Molecular Biology 5.8k
Countries citing papers authored by Xiaoping Su
This map shows the geographic impact of Xiaoping Su's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaoping Su with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaoping Su more than expected).
Fields of papers citing papers by Xiaoping Su
This network shows the impact of papers produced by Xiaoping Su. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaoping Su. The network helps show where Xiaoping Su may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Xiaoping Su, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2023 | 6 | |
| 3 | 2023 | 1 | |
| 4 | 2023 | 33 | |
| 5 | 2022 | 73 | |
| 6 | 2021 | 27 | |
| 7 | 2020 | 20 | |
| 8 | 2020 | 23 | |
| 9 | 2019 | 115 | |
| 10 | 2019 | 6 | |
| 11 | 2017 | 38 | |
| 12 | 2016 | 39 | |
| 13 | 2015 | 68 | |
| 14 | Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6breakdown → | 2015 | 609 |
| 15 | 2014 | 97 | |
| 16 | PD-L1 Expression in Triple-Negative Breast Cancerbreakdown → | 2014 | 1065 |
| 17 | 2014 | 68 | |
| 18 | 2013 | 61 | |
| 19 | 2008 | 95 | |
| 20 | Large-Scale Sequence Analysis of Avian Influenza Isolatesbreakdown → | 2006 | 507 |
About Xiaoping Su
Xiaoping Su is a scholar working on Cancer Research, Hematology, Molecular Biology, Oncology and Genetics, having authored 171 papers that have together received 12.1k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (22 papers), Cancer Genomics and Diagnostics (22 papers), Cancer-related molecular mechanisms research (22 papers), Epigenetics and DNA Methylation (21 papers), Renal and related cancers (17 papers), Acute Myeloid Leukemia Research (15 papers), Acute Lymphoblastic Leukemia research (13 papers) and Immunotherapy and Immune Responses (12 papers). The work is most often cited by research in Cancer Research (3.6k citations), Hematology (2.0k citations), Oncology (2.8k citations), Genetics (933 citations) and Molecular Biology (5.8k citations). Xiaoping Su has collaborated with scholars based in United States, China and France. Frequent co-authors include James R. Downing, Charles G. Mullighan, Christopher B. Miller, Jing Ma, Sheila Shurtleff, Xuetao Cao, Ching‐Hon Pui, Elaine Coustan‐Smith, Letha A. Phillips and James Dalton. Their work appears in journals such as Blood, Cancer Research, Journal of Clinical Oncology, Oncotarget and Proceedings of the National Academy of Sciences.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.